LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

Search

PerkinElmer Inc

Затворен

СекторЗдравеопазване

0

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Ключови измерители

By Trading Economics

Приходи

-8.6M

47M

Продажби

-21M

699M

P/E

Средно за сектора

47.567

77.256

EPS

0.4

Дивидентна доходност

0.31

Марж на печалбата

6.675

Служители

11,000

EBITDA

-14M

181M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+17.8% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.31%

2.33%

Следваща дата на екс-дивидент

16.01.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-815M

10B

Предишно отваряне

0

Предишно затваряне

0

Настроения в новините

By Acuity

18%

82%

37 / 374 Класиране в Healthcare

PerkinElmer Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.11.2025 г., 23:59 ч. UTC

Печалби

Singtel's 1st Half Net Profit Surges

11.11.2025 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11.11.2025 г., 22:21 ч. UTC

Печалби

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11.11.2025 г., 23:52 ч. UTC

Пазарно говорене

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11.11.2025 г., 23:44 ч. UTC

Печалби

Singtel's 1H Net Profit Surges

11.11.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11.11.2025 г., 23:18 ч. UTC

Печалби

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11.11.2025 г., 23:15 ч. UTC

Печалби

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11.11.2025 г., 23:14 ч. UTC

Печалби

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11.11.2025 г., 23:12 ч. UTC

Печалби

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11.11.2025 г., 23:11 ч. UTC

Печалби

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11.11.2025 г., 23:10 ч. UTC

Печалби

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11.11.2025 г., 23:04 ч. UTC

Пазарно говорене

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

11.11.2025 г., 21:50 ч. UTC

Пазарно говорене
Печалби

Health Care Roundup: Market Talk

11.11.2025 г., 21:46 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11.11.2025 г., 21:41 ч. UTC

Печалби

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11.11.2025 г., 21:40 ч. UTC

Печалби

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11.11.2025 г., 21:38 ч. UTC

Печалби

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11.11.2025 г., 21:38 ч. UTC

Печалби

Aristocrat: Final Dividend 49 Australian Cents/Share

11.11.2025 г., 21:37 ч. UTC

Печалби

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11.11.2025 г., 21:36 ч. UTC

Печалби

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11.11.2025 г., 21:35 ч. UTC

Печалби

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q Adj EPS 79c >ALC

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q Rev $2.61B >ALC.EB

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q EPS 48c >ALC.EB

Сравнение с други в отрасъла

Ценова промяна

PerkinElmer Inc Прогноза

Ценова цел

By TipRanks

17.8% нагоре

12-месечна прогноза

Среден 111.1 USD  17.8%

Висок 125 USD

Нисък 100 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за PerkinElmer Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

8

Купи

3

Задържане

0

Продай

Настроение

By Acuity

37 / 374 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat